Small-molecule BET inhibitors (BETi) are demonstrated to noticeably reduce PD-L1 in mRNA and protein levels in several cancers, such as melanoma, triple-negative breast cancer (TNBC), liver cancer, and lung cancer [108,109]. Here, CD274 is linked to cancer.